Author

Janos Laszlo Tanyi

AstraZeneca (United States)ORCID 0000-0002-5657-3698Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Kathleen T. MontoneiD· 2 shared Alizée J GrimmiD· 1 shared Anne I. Kraemer· 1 shared Aspram MinasyaniD· 1 shared Bingwei WangiD· 1 shared Bovannak Stewen ChapiD· 1 shared Charlotte Capt· 1 shared Christina FotopoulouiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Kathleen T. MontoneORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Myeloid cell networks determine reinstatement of original immune environments in recurrent ovarian cancer

Eleonora Ghisoni, Fabrizio Benedetti, Aspram Minasyan, Mathieu Desbuisson, Paula Cunnea, Alizée J Grimm, Noémie Fahr, Charlotte Capt, Nicolas Rayroux, Flavia De Carlo, D. C. Gulhan, Julien Dagher, David Barras, Matteo Morotti, Juan A. Marín‐Jiménez, , Denarda Dangaj Laniti

The paper identifies immune phenotypes and myeloid cell networks in recurrent ovarian cancer that influence prognosis and immune environment reinstatement.

Cancer Cell · Jul 31, 2025Peer-reviewedImmunology

Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Sheng Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen, Meixiao Long, Yi Fan, Kathleen T. Montone, Janos Laszlo Tanyi, Sarah H. Kim, , Xiaowen Hu

This study identifies PRMT inhibitors as effective combinational therapies with PARP inhibitors to sensitize HR-proficient ovarian and breast cancer cells to treatment.

eLife · Jul 17, 2024Peer-reviewedCancer Biology